Repository logo
 
Publication

Combination of elacridar with imatinib modulates resistance associated with drug efflux transporters in chronic myeloid leukemia

2022-05-17Journal article Open access
Simple item page
dc.contributor.authorAlves, Raquel
dc.contributor.authorGonçalves, Ana Cristina
dc.contributor.authorJorge, Joana
dc.contributor.authorAlmeida, António M.
dc.contributor.authorSarmento-Ribeiro, Ana Bela
dc.date.accessioned2022-06-07T08:38:15Z
dc.date.available2022-06-07T08:38:15Z
dc.date.issued2022-05-17
dc.description.abstractMultidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in BCR-ABL1 and intracellular drug concentration, controlled by SLC and ABC transporters. We evaluate the therapeutic potential of a P-glycoprotein and BCRP inhibitor, elacridar, in sensitive (K562 and LAMA-84) and imatinib-resistant (K562-RC and K562-RD) CML cell lines as monotherapy and combined with imatinib. Cell viability was analyzed by resazurin assay. Drug transporter activity, cell death, cell proliferation rate, and cell cycle distribution were analyzed by flow cytometry. Both resistant models presented an increased activity of BCRP and P-gP compared to K562 cells. Elacridar as monotherapy did not reach IC50 in any CML models but activated apoptosis without cytostatic effect. Nevertheless, the association of elacridar (250 nM) with imatinib overcomes resistance, re-sensitizing K562-RC and K562-RD cells with five and ten times lower imatinib concentrations, respectively. Drug combination induced apoptosis with increased cleaved-caspases-3, cleaved-PARP and DNA damage, reduced cell proliferation rate, and arrested CML cells in the S phase. These data suggest that elacridar combined with imatinib might represent a new therapeutic option for overcoming TKI resistance involving efflux transporters. View Full-Textpt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.3390/biomedicines10051158pt_PT
dc.identifier.eid85130788531
dc.identifier.issn2227-9059
dc.identifier.pmcPMC9138473
dc.identifier.pmid35625893
dc.identifier.urihttp://hdl.handle.net/10400.14/37831
dc.identifier.wos000801263300001
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectImatinib resistancept_PT
dc.subjectABC transporter inhibitorspt_PT
dc.subjectElacridarpt_PT
dc.subjectApoptosispt_PT
dc.titleCombination of elacridar with imatinib modulates resistance associated with drug efflux transporters in chronic myeloid leukemiapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue2pt_PT
oaire.citation.titleBiomedicinespt_PT
oaire.citation.volume10pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
44140042.pdf
Size:
2.2 MB
Format:
Adobe Portable Document Format
Download

Collections

CIIS - Contribuições em Revistas Científicas / Contribution to Journals